TG THERAPEUTICS, INC. Payments for Repurchase of Equity
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- TG THERAPEUTICS, INC. payments for repurchase of equity for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- TG THERAPEUTICS, INC. payments for repurchase of equity for the quarter ending 2026-03-31 was $99.99M, a 1533.06% increase year-over-year.
- TG THERAPEUTICS, INC. payments for repurchase of equity for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- TG THERAPEUTICS, INC. payments for repurchase of equity for the quarter ending 2025-09-30 was $78.24M, a 3540.86% increase year-over-year.
- TG THERAPEUTICS, INC. payments for repurchase of equity for fiscal 2025 was $91.24M, a 941.55% increase from fiscal 2024.
- TG THERAPEUTICS, INC. payments for repurchase of equity for fiscal 2024 was $8.76M.
- TG THERAPEUTICS, INC. payments for repurchase of equity for fiscal 2023 was $0.00.
- TG THERAPEUTICS, INC. payments for repurchase of equity for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Equity 3 month | Payments for Repurchase of Equity 12 month |
|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $178.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $99.99M 10-Q · filed 2026-05-06 | $185.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $91.24M 10-K · filed 2026-02-27 |
| 2025-09-30 | $78.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $97.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $6.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $21.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.12M 10-Q · filed 2026-05-06 | $14.88M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $6.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $8.76M 10-K · filed 2026-02-27 |
| 2024-09-30 | $2.15M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $2.15M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $0.00 10-K · filed 2026-02-27 |
| 2022-12-31 | $0.00 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |